Pediatrix Medical Group, Inc. Stock Price, News & Analysis

Pediatrix Medical Group (NYSE: MD) reported Q3 2022 earnings of $0.35 per share, with net revenue of $490 million, down from $492.9 million year-over-year. Adjusted EBITDA was $58 million, reflecting operational challenges in billing and collections, and a decline in reimbursement from commercial payors. Despite these issues, Pediatrix's Adjusted EPS from continuing operations was $0.40. The company anticipates 2022 Adjusted EBITDA will range from $240 million to $245 million, indicating strategic efforts are underway to enhance revenue cycle management.

Pediatrix Medical Group, Inc. (NYSE: MD) will hold an investor conference call on November 3, 2022, at 9:00 a.m. ET to discuss its quarterly operational results for the period ending September 30, 2022. A detailed press release will precede the call, providing insights into the company's financial performance. The call will be accessible via webcast on the company's investor relations page. Pediatrix is a leading provider of physician services focused on pediatrics and obstetrics, serving across 37 states and Puerto Rico.

Pediatrix Medical Group, Inc. (NYSE: MD) commented on the final rule from August 19, 2022, regarding the No Surprises Act. The rule stipulates that the qualifying payment amount (QPA) is one of several factors considered in the independent dispute resolution (IDR) process for out-of-network payment rates. Key factors include provider training, market share, patient acuity, facility status, and good faith negotiations. Pediatrix emphasizes the importance of safeguarding against potential payor manipulation of the QPA and is committed to ensuring compliance with the new rules for the continuity of care.

Pediatrix Medical Group, Inc. (NYSE: MD) reported earnings from continuing operations of $0.36 per share for Q2 2022, with Adjusted EPS of $0.47. The company achieved net revenue of $486 million, a 2.7% increase from the prior year, primarily due to acquisitions. However, same-unit revenue decreased by 1.3%. Operating expenses rose to $330.8 million, reflecting acquisitions. Adjusted EBITDA for Q2 was $66 million. Cash from continuing operations was $81.6 million. The company anticipates 2022 Adjusted EBITDA between $260-$270 million.

Pediatrix Medical Group (NYSE: MD) will host an investor conference call on August 4, 2022, at 9:00 a.m. ET, to discuss its Q2 2022 operational results. A detailed press release will precede the call, issued before market opening on the same day. Pediatrix is a leading provider of physician services, focusing on women, babies, and children through over 4,800 affiliated clinicians across 37 states and Puerto Rico.

For further information, visit www.pediatrix.com/investors.

Mednax, Inc. (NYSE: MD) has announced its corporate name change to Pediatrix Medical Group, Inc., effective July 1, 2022. This rebranding emphasizes its commitment as a premier provider of healthcare services for women, infants, and children. CEO Mark S. Ordan highlighted the significance of returning to the well-respected Pediatrix name. Shareholders are not required to take any action as existing shares will automatically represent the new name. This transition marks a strategic focus on pediatrics and obstetrics, following the company's extensive service history since its inception in 1979.

Mednax, Inc. announces the appointment of James D. Swift, M.D. as Chief Operating Officer and Curtis B. Pickert, M.D. as Chief Physician Executive, emphasizing their commitment to high-quality patient care and operational growth. Both doctors have over a decade of leadership experience within the company. Dr. Swift, previously Executive Vice President and Chief Development Officer, and Dr. Pickert, former Executive Vice President of Clinical Services, aim to enhance Mednax's service delivery across various specialties.

Mednax, Inc. (NYSE: MD) reported a loss from continuing operations of $0.25 per share for Q1 2022, driven by a $57 million pretax loss on debt extinguishment. Net revenue reached $482 million, marking an increase from $446.8 million in Q1 2021. Adjusted EPS improved to $0.33, up from $0.24 in the prior year. The company experienced growth in patient volume, with same-unit revenue rising by 1.3%. However, operational challenges persisted, with a notable decrease in investment income and increased expenses related to practice salaries and benefits.

Mednax, Inc. (NYSE: MD) announced an investor conference call scheduled for April 28, 2022, at 9:00 a.m. ET. The call will discuss operational results for the quarter ending March 31, 2022. A detailed press release will be issued that morning prior to market opening. Mednax is a national medical group providing specialized physician services focused on women, babies, and children through its Pediatrix brand. The company emphasizes coordinated care across various specialties and has a network of over 4,700 clinicians in 38 states and Puerto Rico.